CD6 and multiple sclerosis: The recent marketing of a humanized anti-CD6 mAb (itolizumab) (3, 4), together with the identification of CD6 gene as a multiple sclerosis susceptibility locus (5, 6), has renewed the interest in the study of this relatively neglected lymphocyte receptor.